Cargando…

The diagnostic role of complete MICM-P in metastatic carcinoma of bone marrow (MCBM) presented with atypical symptoms: A 7-year retrospective study of 45 cases in a single center

Metastatic carcinoma of bone marrow (MCBM) tends to present with atypical symptoms and can be easily misdiagnosed or miss diagnosed. This study was conducted to investigate the clinical-pathological and hematological characteristics of MCBM patients in order to develop strategies for early detection...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Chao, Wang, Zhiqiong, Tong, Xiwen, Li, Yi, Liu, Xian, Huang, Lifang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9666179/
https://www.ncbi.nlm.nih.gov/pubmed/36397369
http://dx.doi.org/10.1097/MD.0000000000031731
_version_ 1784831445840166912
author Wang, Chao
Wang, Zhiqiong
Tong, Xiwen
Li, Yi
Liu, Xian
Huang, Lifang
author_facet Wang, Chao
Wang, Zhiqiong
Tong, Xiwen
Li, Yi
Liu, Xian
Huang, Lifang
author_sort Wang, Chao
collection PubMed
description Metastatic carcinoma of bone marrow (MCBM) tends to present with atypical symptoms and can be easily misdiagnosed or miss diagnosed. This study was conducted to investigate the clinical-pathological and hematological characteristics of MCBM patients in order to develop strategies for early detection, staging, treatment selection and prognosis predicting. We retrospectively analyzed 45 patients with MCBM diagnosed by bone marrow biopsy in our hospital during the past 7 years. The clinical symptoms, hemogram and myelogram features, Hematoxylin and eosin staining and immunohistochemistry staining of bone marrow biopsies, location of primary carcinoma and corresponding treatment of the 45 MCBM patients were analyzed in this study. In total, 35 (77.9%) of all patients presented pains including bone pain (73.3%) as the main manifestation, and 37 (82.2%) patients had anemia. Metastatic cancer cells were found in only 22 patients (48.9%) upon bone marrow smear examination, but in all 45 patients by bone marrow biopsy. The bone marrow of 18 (40.0%) patients was dry extraction. Distribution of metastatic carcinoma was diffuse in 20 (44.4%) patients and multi-focal in 25 (55.6%) patients, complicated with myelofibrosis in 34 (75.6%) patients. For bone marrow biopsy immunohistochemistry, 97.8% of the patients were CD45-negative, while 75.6% of the patients were Cytokeratin-positive. There were 30 patients (66.7%) identified with primary malignancies. The overall survival (OS) of 1 year for MCBM patients was 6.7%. There was a trend that patients with cancer of known primary obtained better prognosis according to the survival curve, but the finding was not statistically significant with Log-rank P = .160. Complete MICM-P plays a significant role in early diagnosis of MCBM. Bone marrow biopsy combined with immunohistochemistry is an underappreciated method for the diagnosis of MCBM, which should be taken as part of regular tests as well as bone marrow smear. Understanding the clinical-pathological and hematological characteristics of MCBM and conducting bone marrow biopsy in time are of great significance for early detection and treatment selection.
format Online
Article
Text
id pubmed-9666179
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Lippincott Williams & Wilkins
record_format MEDLINE/PubMed
spelling pubmed-96661792022-11-16 The diagnostic role of complete MICM-P in metastatic carcinoma of bone marrow (MCBM) presented with atypical symptoms: A 7-year retrospective study of 45 cases in a single center Wang, Chao Wang, Zhiqiong Tong, Xiwen Li, Yi Liu, Xian Huang, Lifang Medicine (Baltimore) 4100 Metastatic carcinoma of bone marrow (MCBM) tends to present with atypical symptoms and can be easily misdiagnosed or miss diagnosed. This study was conducted to investigate the clinical-pathological and hematological characteristics of MCBM patients in order to develop strategies for early detection, staging, treatment selection and prognosis predicting. We retrospectively analyzed 45 patients with MCBM diagnosed by bone marrow biopsy in our hospital during the past 7 years. The clinical symptoms, hemogram and myelogram features, Hematoxylin and eosin staining and immunohistochemistry staining of bone marrow biopsies, location of primary carcinoma and corresponding treatment of the 45 MCBM patients were analyzed in this study. In total, 35 (77.9%) of all patients presented pains including bone pain (73.3%) as the main manifestation, and 37 (82.2%) patients had anemia. Metastatic cancer cells were found in only 22 patients (48.9%) upon bone marrow smear examination, but in all 45 patients by bone marrow biopsy. The bone marrow of 18 (40.0%) patients was dry extraction. Distribution of metastatic carcinoma was diffuse in 20 (44.4%) patients and multi-focal in 25 (55.6%) patients, complicated with myelofibrosis in 34 (75.6%) patients. For bone marrow biopsy immunohistochemistry, 97.8% of the patients were CD45-negative, while 75.6% of the patients were Cytokeratin-positive. There were 30 patients (66.7%) identified with primary malignancies. The overall survival (OS) of 1 year for MCBM patients was 6.7%. There was a trend that patients with cancer of known primary obtained better prognosis according to the survival curve, but the finding was not statistically significant with Log-rank P = .160. Complete MICM-P plays a significant role in early diagnosis of MCBM. Bone marrow biopsy combined with immunohistochemistry is an underappreciated method for the diagnosis of MCBM, which should be taken as part of regular tests as well as bone marrow smear. Understanding the clinical-pathological and hematological characteristics of MCBM and conducting bone marrow biopsy in time are of great significance for early detection and treatment selection. Lippincott Williams & Wilkins 2022-11-11 /pmc/articles/PMC9666179/ /pubmed/36397369 http://dx.doi.org/10.1097/MD.0000000000031731 Text en Copyright © 2022 the Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the Creative Commons Attribution License 4.0 (CCBY) (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle 4100
Wang, Chao
Wang, Zhiqiong
Tong, Xiwen
Li, Yi
Liu, Xian
Huang, Lifang
The diagnostic role of complete MICM-P in metastatic carcinoma of bone marrow (MCBM) presented with atypical symptoms: A 7-year retrospective study of 45 cases in a single center
title The diagnostic role of complete MICM-P in metastatic carcinoma of bone marrow (MCBM) presented with atypical symptoms: A 7-year retrospective study of 45 cases in a single center
title_full The diagnostic role of complete MICM-P in metastatic carcinoma of bone marrow (MCBM) presented with atypical symptoms: A 7-year retrospective study of 45 cases in a single center
title_fullStr The diagnostic role of complete MICM-P in metastatic carcinoma of bone marrow (MCBM) presented with atypical symptoms: A 7-year retrospective study of 45 cases in a single center
title_full_unstemmed The diagnostic role of complete MICM-P in metastatic carcinoma of bone marrow (MCBM) presented with atypical symptoms: A 7-year retrospective study of 45 cases in a single center
title_short The diagnostic role of complete MICM-P in metastatic carcinoma of bone marrow (MCBM) presented with atypical symptoms: A 7-year retrospective study of 45 cases in a single center
title_sort diagnostic role of complete micm-p in metastatic carcinoma of bone marrow (mcbm) presented with atypical symptoms: a 7-year retrospective study of 45 cases in a single center
topic 4100
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9666179/
https://www.ncbi.nlm.nih.gov/pubmed/36397369
http://dx.doi.org/10.1097/MD.0000000000031731
work_keys_str_mv AT wangchao thediagnosticroleofcompletemicmpinmetastaticcarcinomaofbonemarrowmcbmpresentedwithatypicalsymptomsa7yearretrospectivestudyof45casesinasinglecenter
AT wangzhiqiong thediagnosticroleofcompletemicmpinmetastaticcarcinomaofbonemarrowmcbmpresentedwithatypicalsymptomsa7yearretrospectivestudyof45casesinasinglecenter
AT tongxiwen thediagnosticroleofcompletemicmpinmetastaticcarcinomaofbonemarrowmcbmpresentedwithatypicalsymptomsa7yearretrospectivestudyof45casesinasinglecenter
AT liyi thediagnosticroleofcompletemicmpinmetastaticcarcinomaofbonemarrowmcbmpresentedwithatypicalsymptomsa7yearretrospectivestudyof45casesinasinglecenter
AT liuxian thediagnosticroleofcompletemicmpinmetastaticcarcinomaofbonemarrowmcbmpresentedwithatypicalsymptomsa7yearretrospectivestudyof45casesinasinglecenter
AT huanglifang thediagnosticroleofcompletemicmpinmetastaticcarcinomaofbonemarrowmcbmpresentedwithatypicalsymptomsa7yearretrospectivestudyof45casesinasinglecenter
AT wangchao diagnosticroleofcompletemicmpinmetastaticcarcinomaofbonemarrowmcbmpresentedwithatypicalsymptomsa7yearretrospectivestudyof45casesinasinglecenter
AT wangzhiqiong diagnosticroleofcompletemicmpinmetastaticcarcinomaofbonemarrowmcbmpresentedwithatypicalsymptomsa7yearretrospectivestudyof45casesinasinglecenter
AT tongxiwen diagnosticroleofcompletemicmpinmetastaticcarcinomaofbonemarrowmcbmpresentedwithatypicalsymptomsa7yearretrospectivestudyof45casesinasinglecenter
AT liyi diagnosticroleofcompletemicmpinmetastaticcarcinomaofbonemarrowmcbmpresentedwithatypicalsymptomsa7yearretrospectivestudyof45casesinasinglecenter
AT liuxian diagnosticroleofcompletemicmpinmetastaticcarcinomaofbonemarrowmcbmpresentedwithatypicalsymptomsa7yearretrospectivestudyof45casesinasinglecenter
AT huanglifang diagnosticroleofcompletemicmpinmetastaticcarcinomaofbonemarrowmcbmpresentedwithatypicalsymptomsa7yearretrospectivestudyof45casesinasinglecenter